Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
Date:11/9/2011

83$ 150,669  Accounts receivable

2,0153,499  Other current assets

2,4862,638  Land, property & equipment, net

85,24591,533  Acquired technology & other non-current assets

17,37018,023Total assets

$ 184,999$ 266,362Liabilities and Stockholders' Equity  Accounts payable and accrued liabilities

$   9,608$   10,680  Total deferred revenues

45,20148,077  Total derivative liabilities

1,2772,271  Total note payable to Siegfried

3,68610,361  Total note payable to Deerfield (2)

13,76937,777  Total lease financing obligations & other long-term liabilities

76,31977,181  Total stockholders' equity

35,13980,015Total liabilities & stockholders' equity

$ 184,999$ 266,362(1)

The Condensed Consolidated Balance Sheet Data has been derived from the audited financial statements as of that date.(2)

The outstanding principal balance of the note payable to Deerfield was $22.3 million at September 30, 2011 and $60.0 million at December 31, 2010.Contacts:

Arena Pharmaceuticals, Inc.

Robert E. Hoffman

Vice President, Finance and Chief Financial Officer858.453.7200, ext. 222

Investor Inquiries: Russo Partners

Cindy McGee, Vice President

cindy.mcgee@russopartnersllc.com

619.308.6538Media Inquiries: Russo Partners

David Schull, President

david.schull@russopartnersllc.com

858.717.2310
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
2. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
3. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
4. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
5. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
6. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
7. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
8. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
9. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
10. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
11. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Calif. , Oct. 22, 2014  AcelRx ... announced that results from the  IAP310 study have ... Medicine (RAPM), a peer-reviewed journal with broad, ... 3 trial evaluating the safety and efficacy of ... tablet system (SSTS), for the treatment of post-operative ...
(Date:10/20/2014)... , 20 de octubre de 2014 /PRNewswire/ ... el campo de la pulmonología intervencional, anunció hoy ... RENEW, casi 3 meses antes de lo programado. El ... exención de dispositivo de investigación (IDE) aprobada por ... el sistema de espiral de reducción de volumen ...
(Date:10/20/2014)... BioNano Genomics announced today achievement of a major milestone ... at 30X depth, sufficient for a genome map, in 24 ... and demonstrated for the IrysChip TM V2, the high-throughput ... will be rolled out to BioNano,s collaborators and customers over ... at the American Society for Human Genetics (ASHG) 2014 ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
... Inhibitor-, SOUTH SAN FRANCISCO, Calif., Jan. 7 ... has initiated a phase 1/2 trial,of XL184 in patients ... disease while on a regimen containing erlotinib., XL184 ... RET and,VEGFR receptor tyrosine kinases. In the initial phase ...
... scientists today,report that the genetic variant on chromosome ... of heart attack is also associated with up ... (AAA) and intracranial,aneurysm (IA). This is the first ... condition. The paper, entitled ,The same sequence,variant on ...
Cached Medicine Technology:Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 2Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 3Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 4Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease 2Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease 3
(Date:10/22/2014)... Mission Viejo, CA (PRWEB) October 22, 2014 ... that Jay Cormier, Sr. Vice President of Sales, will ... at the upcoming Meetings Technology Expo on October 28, ... will also be hosting a booth as well as ... on how Lintelus Meeting can create a more engaging ...
(Date:10/22/2014)... By Maureen Salamon ... -- Black women undergoing in vitro fertilization (IVF) are only ... using the popular assisted reproduction technique, new research indicates, and ... In the study, about 31 percent of white patients ... black patients. Analyzing more than 4,000 IVF cycles over ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
(Date:10/20/2014)... 2014 With a mere 19 days ... made a brief fundraising stop at the  Law ... Fresh from a debate last night with his opponent ... for the first seven minutes because Crist had an ... the incident in one word: "weird." , Before touching ...
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, MD, Ob/Gyn ... Inc., A Division of MaternOhio Clinical Associates, Inc., who ... patients annually. Dr. Murphy will provide a full range ... women’s life. She is accepting new patients at two ... , Dr. Murphy offers a wide variety of services ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
... (HealthDay News) -- Feelings of shame, social isolation and rejection ... finds. The findings may help explain why depression is ... other kinds of cancer, according to the researchers at the ... association with tobacco use, lung cancer is commonly viewed as ...
... a key mechanism that causes breast cancer to spread. The ... journal Molecular Cell , enhances our knowledge about the ... for a lethal form of invasive breast cancer that is ... ErbB2 has been linked with aggressive forms of breast cancer ...
... irritable bowel syndrome (IBS) have a significantly greater prevalence ... as well as physical, emotional and sexual abuse, according ... Hepatology, the official journal of the American Gastroenterological ... associated with the development of irritable bowel syndrome, particularly ...
... most common kidney cancer subtype, face a low risk of ... key findings of a multi-centre study of nearly 600 patients ... BJUI . "Because papillary renal cell ... patients, the small number of patients enrolled in individual studies ...
... strategy includes a plan to ensure that General Practitioners (GPs) ... 23 March 2012, downloadable from http://www.homeoffice.gov.uk/publications/ ). There is ... The big question is, what should GPs say to their ... scientific journal Addiction analysed the advice given by ...
... PHILADELPHIA Patients with end-stage liver disease complicated by ... carcinoma (HCC) are less likely to die or ... a new liver than those with other complications of ... Perelman School of Medicine at the University of Pennsylvania. ...
Cached Medicine News:Health News:Stigma, Shame Can Worsen Depression in Lung Cancer Patients 2Health News:Researchers identify mechanism that makes breast cancer invasive 2Health News:Childhood traumatic experiences associated with adult IBS symptoms 2Health News:Kidney cancer subtype study finds low recurrence and cancer death rates 2Health News:Penn researchers call for a re-examination of transplant waitlist prioritization 2Health News:Penn researchers call for a re-examination of transplant waitlist prioritization 3
... Wrist Fixator is now available in a ... necessary instrumentation. The surgical technique is printed ... reference. , ,This fixator allows the surgeon ... making multipaner adjustments in the frame via ...
... The WristJack External Fixation System for ... palmar tilt, radial inclination, length and rotation. ... to place the wrist into extension without ... are easily performed in the surgeons office. ...
... slender design contributes to overall low-profile frame ... The Connecting Clamp allows connection of 3.0 ... Uses 3.0 mm Carbon Fiber Rods. The ... to predrill and provide more stability and ...
The DFS MiniFixator is a lightweight, external device for the treatment of small bone fractures and osteotomies....
Medicine Products: